Skip to main content
Explore URMC
URMC / Research / Clinical Trials / Study Details

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Research Question:
What is the immediate safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplant?

Basic Study Information

Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS) who are considered eligible for allogeneic stem cell transplant by the transplant team at WCI (Wilmot Cancer Institute) will be enrolled in the study. Patients will receive Melphalan on day -2 and HBO (Hyperbaric Oxygen) therapy on day 0 of the transplant. After neutrophil recovery is documented, the patients will be seen in clinic at least weekly through day +100.

Location: University of Rochester Medical Center
Study Reference #: ubmt19163

Lead Researcher (Principal Investigator)

Lead Researcher:  Omar Aljitawi

Study Contact Information

Study Coordinator: Kaitlyn Burrows
Phone: (585) 275-5150

Additional Study Details

Return to Search